Shares of MDxHealth SA (NASDAQ:MDXH – Get Free Report) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $4.6250.
A number of equities research analysts have recently issued reports on MDXH shares. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. BTIG Research lowered their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. TD Cowen reissued a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th.
View Our Latest Report on MDxHealth
MDxHealth Stock Performance
MDxHealth (NASDAQ:MDXH – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%.The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. On average, sell-side analysts predict that MDxHealth will post -0.6 earnings per share for the current year.
Institutional Investors Weigh In On MDxHealth
A number of institutional investors and hedge funds have recently bought and sold shares of MDXH. Kennedy Capital Management LLC purchased a new stake in MDxHealth in the third quarter valued at approximately $1,826,000. Marshall Wace LLP purchased a new stake in MDxHealth in the fourth quarter valued at approximately $609,000. Mink Brook Asset Management LLC purchased a new stake in MDxHealth in the third quarter valued at approximately $743,000. Panoramic Capital LLC purchased a new stake in MDxHealth in the third quarter valued at approximately $721,000. Finally, FreeGulliver LLC raised its stake in MDxHealth by 104.7% in the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after purchasing an additional 129,348 shares in the last quarter.
MDxHealth Company Profile
MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.
MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.
Featured Articles
- Five stocks we like better than MDxHealth
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
